|
Where There's Smoke, There's Fire: Inflammation Drives MDS
|
Jul 2020
|
Trends in immunology
|
myelodysplastic syndromes (MDS)
|
|
When is iron overload deleterious, and when and how should iron chelation therapy be administered in myelodysplastic syndromes?
|
Dec 2013
|
Best Pract Res Clin Haematol
|
myelodysplastic syndromes (MDS)
|
|
Very Severe Aplastic Anemia During Treatment With Doxycycline
|
Oct 2016
|
Am J Ther.
|
aplastic anemia
|
|
Venetoclax and Hypomethylating Agents (HMAs) Induce High Response Rates in MDS, Including Patients After HMA Therapy Failure
|
Jul 2020
|
Blood Advances
|
myelodysplastic syndromes (MDS)
|
|
Venetoclax and hypomethylating agent therapy in high risk myelodysplastic syndromes: a retrospective evaluation of a real-world experience
|
Nov 2020
|
Leukemia & Lymphoma
|
myelodysplastic syndromes (MDS)
|
|
Variations in erythropoiesis-stimulating agent administration in transfusion-dependent myelodysplastic syndromes impact response
|
Mar 2015
|
Leuk Res
|
myelodysplastic syndromes (MDS)
|
|
Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodyspla
|
Feb 2015
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
|
Validation of the revised international prognostic scoring system in treated patients with myelodysplastic syndromes.
|
Apr 2013
|
Am J Hematol
|
myelodysplastic syndromes (MDS)
|
|
Validation of International Working Group response criteria in higher-risk myelodysplastic syndromes: A report on behalf of the MDS Clinical Research Consortium
|
Dec 2020
|
Cancer Medicine
|
myelodysplastic syndromes (MDS)
|
|
Validation of a Prognostic Model and the Impact of Mutations in Patients With Lower-Risk Myelodysplastic Syndromes
|
Aug 2012
|
J Clin Oncol
|
myelodysplastic syndromes (MDS)
|
